{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:33:56Z","timestamp":1761658436077,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004700","name":"Taipei Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jmii.2022.08.012","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T02:25:38Z","timestamp":1662603938000},"page":"344-350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of a combination antibiogram for empirical treatments of Pseudomonas aeruginosa at a university-affiliated teaching hospital"],"prefix":"10.1016","volume":"56","author":[{"given":"Ming-Ying","family":"Ai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huai-En","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Yu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Chuan","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bi-Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Er-Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Hsin","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuarn-Jang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2022.08.012_bib1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fcimb.2017.00039","article-title":"Pseudomonas aeruginosa lifestyle: a paradigm for adaptation, survival, and persistence","volume":"7","author":"Moradali","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jmii.2022.08.012_bib2","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.2147\/IDR.S268744","article-title":"Risk factors for mortality of inpatients with Pseudomonas aeruginosa bacteremia in China: impact of resistance Profile in the mortality","volume":"13","author":"Zhang","year":"2020","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jmii.2022.08.012_bib3","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1128\/AAC.00627-10","article-title":"Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis","volume":"54","author":"Paul","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.08.012_bib4","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1021\/jo400236f","article-title":"Overcoming resistance to \u03b2-Lactam antibiotics","volume":"78","author":"Worthington","year":"2013","journal-title":"J Org Chem"},{"key":"10.1016\/j.jmii.2022.08.012_bib5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fpubh.2019.00151","article-title":"The \u201cOld\u201d and the \u201cNew\u201d antibiotics for MDR gram-negative pathogens: for whom, when, and how","volume":"7","author":"Karaiskos","year":"2019","journal-title":"Front Public Health"},{"key":"10.1016\/j.jmii.2022.08.012_bib6","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1586\/erp.10.49","article-title":"Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes","volume":"10","author":"Hirsch","year":"2010","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.jmii.2022.08.012_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-51711-x","article-title":"Monotherapy versus combination therapy for multidrug-resistant gram-negative infections: systematic review and meta-analysis","volume":"9","author":"Schmid","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jmii.2022.08.012_bib8","article-title":"Antimicrobial treatment of monomicrobial phenotypic carbapenem-resistant Klebsiella pneumoniae bacteremia: two are better than one","author":"Tsai","year":"2021","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2022.08.012_bib9","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4065\/mcp.2010.0639","article-title":"General principles of antimicrobial therapy","volume":"86","author":"Leekha","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jmii.2022.08.012_bib10","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/jac\/dkq494","article-title":"Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes","volume":"66","author":"Gudiol","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2022.08.012_bib11","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1128\/AAC.49.4.1306-1311.2005","article-title":"Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment","volume":"49","author":"Micek","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.08.012_bib12","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1086\/377200","article-title":"Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome","volume":"37","author":"Kang","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2022.08.012_bib13","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ijantimicag.2007.05.022","article-title":"Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved?","volume":"30","author":"Bhat","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jmii.2022.08.012_bib14","first-page":"828","article-title":"Creation of a combination antibiogram for Pseudomonas aeruginosa in a pediatric intensive care unit","volume":"26","author":"Thompson","year":"2021","journal-title":"J Pediatr Pharmacol Therapeut"},{"article-title":"Performance standards for antimicrobial susceptibility testing","year":"2017","series-title":"CLSI supplement M100","key":"10.1016\/j.jmii.2022.08.012_bib15"},{"key":"10.1016\/j.jmii.2022.08.012_bib16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jmii.2014.01.005","article-title":"Carbapenem-resistant Pseudomonas aeruginosa in Taiwan: prevalence, risk factors, and impact on outcome of infections","volume":"49","author":"Lin","year":"2016","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2022.08.012_bib17","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America an3d the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2022.08.012_bib18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/1078155215586081","article-title":"Development of a combination antibiogram for Pseudomonas aeruginosa bacteremia in an oncology population","volume":"22","author":"Smith","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.jmii.2022.08.012_bib19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.tibtech.2012.12.006","article-title":"Combination Approaches to combat multi-drug resistant bacteria","volume":"31","author":"Worthington","year":"2013","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.jmii.2022.08.012_bib20","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1158\/0008-5472.CAN-17-1201","article-title":"Combination therapy and the evolution of resistance: the theoretical merits of synergism and antagonism in cancer","volume":"78","author":"Saputra","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.jmii.2022.08.012_bib21","first-page":"11","article-title":"Risk factors and outcomes for multidrug-resistant Gram-negative bacilli bacteremia","volume":"5","author":"Patolia","year":"2018","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.jmii.2022.08.012_bib22","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/CMR.05041-11","article-title":"Combination therapy for treatment of infections with gram-negative bacteria","volume":"25","author":"Tamma","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jmii.2022.08.012_bib23","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1128\/AAC.00462-11","article-title":"Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis","volume":"56","author":"Retamar","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.08.012_bib24","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1128\/AAC.49.4.1306-1311.2005","article-title":"Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment","volume":"49","author":"Micek","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2022.08.012_bib25","first-page":"245","article-title":"Antimicrobial stewardship","volume":"25","author":"Tamma","year":"2011","journal-title":"Infect Dis Clin"},{"key":"10.1016\/j.jmii.2022.08.012_bib26","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1086\/503175","article-title":"Identification of optimal combinations for empirical dual antimicrobial therapy of Pseudomonas aeruginosa infection: potential role of a Combination Antibiogram","volume":"27","author":"Mizuta","year":"2006","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jmii.2022.08.012_bib27","first-page":"165","article-title":"Results of a local combination therapy antibiogram for Pseudomonas aeruginosa isolates: is double worth the trouble?","volume":"4","author":"Song","year":"2017","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.jmii.2022.08.012_bib28","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/1471-2334-12-308","article-title":"Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosapneumonia","volume":"12","author":"Park","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jmii.2022.08.012_bib29","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/jac\/dki030","article-title":"Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa","volume":"55","author":"Dupont","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jmii.2022.08.012_bib30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijantimicag.2009.11.007","article-title":"Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use","volume":"35","author":"Lee","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jmii.2022.08.012_bib31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jmii.2012.11.006","article-title":"Epidemiology and antimicrobial resistance among commonly encountered bacteria associated with infections and colonization in intensive care units in a university-affiliated hospital in Shanghai","volume":"47","author":"Tan","year":"2014","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2022.08.012_bib32","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/infdis\/128.1.63","article-title":"Concentrations of gentamicin and carbenicillin in bronchial secretions","volume":"128","author":"Pennington","year":"1973","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jmii.2022.08.012_bib33","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jcf.2009.08.004","article-title":"Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review","volume":"8","author":"Ratjen","year":"2009","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118222001414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118222001414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:29:23Z","timestamp":1761658163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118222001414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1684118222001414"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2022.08.012","relation":{},"ISSN":["1684-1182"],"issn-type":[{"type":"print","value":"1684-1182"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a combination antibiogram for empirical treatments of Pseudomonas aeruginosa at a university-affiliated teaching hospital","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2022.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}